32 completed, 4 recruiting, 3 not yet recruiting, 3 terminated. 46 Phase 1, 15 Phase 2.
Follow Seizures: new trials by email Literature Review of Seizures trials Research Report on Seizures
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Basket Clinical Study to Assess Glycerol Tributyrate in Patients With Mitochondrial Encephalopathy, Lactic Acidosis, Stroke-like Episodes (MELAS) or Leber's Hereditary Optic Neuropathy-Plus (LHON-Plus) Glycerol Tributyrate - MELAS Syndrome, Lebers Hereditory Optic Neuropathy With Extra Ocular Symptoms (LHON-Plus) | Phase 1 / Phase 2 | Not yet recruiting | George Washington University | 24 | 2027-03-01 | 2026-10-05 |
| A Clinical Study to Assess the Safety, Tolerability and Pharmacokinetics of Orally Administered Cannabidiol Capsules (AVAT-121) and Epidyolex® in Healthy Adults AVAT-121, AVAT-121 and Epidyolex® - Focal Onset Seizure | Phase 1 | Not yet recruiting | Avata Biosciences Holdings Ltd | 44 | 2026-10-20 | 2026-11-05 |
| The TTM and ASM Trial Prophylactic ASM, Hypothermic, Normothermic - Critical Care Medicine, Emergency Medical Services | Phase 1 | Not yet recruiting | National Taiwan University Hospital | 100 | 2026-09-17 | 2026-10-07 |
| Effects of a Sigle Dose of Ayahuasca in Patients With Psychogenic Non-epileptic Seizures: an Open Label Clinical Trial Ayahuasca - Non Epileptic Seizures | Phase 1 / Phase 2 | Recruiting | University of Sao Paulo | 15 | 2026-07-01 | 2026-08-05 |
| A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures CBD-OS - Focal Seizures | Phase 1 | Recruiting | Jazz Pharmaceuticals | 100 | 2025-11-26 | 2026-10-29 |
| BHV-7000 Responsive Neurostimulation System (RNS) Study BHV-700 - Epilepsy, Seizures | Phase 1 | Completed | Yale University | 5 | 2025-10-07 | 2026-10-21 |
| Ketogenic Diet for Prevention of Epileptic Spasms in Infantile Onset Genetic Epilepsies Ketogenic diet - Developmental and Epileptic Encephalopathies, Epileptic Spasms | Phase 1 | Terminated | Heather Olson | 1 | 2025-08-11 | 2026-10-14 |
| Safety, Tolerability, and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of iQ-007 iQ-007, Placebo - Drug Resistant Epilepsy, Focal Seizure | Phase 1 | Active not recruiting | iQure Australia Pty Ltd | 72 | 2025-04-08 | 2025-12-29 |
| Investigation of Blood-Brain-Barrier Breakdown Using Manganese Magnetic Resonance Imaging in Drug-Resistant Epilepsy Mangafodipir, Gadolinium - Epilepsy | Phase 1 | Recruiting | National Institute of Neurological Disorders and Stroke (NINDS) | 40 | 2024-11-19 | 2026-10-29 |
| A Safety, Tolerability, and Preliminary Efficacy of Low-intensity Focused Ultrasound Neuromodulation in Patients With Drug-resistant Epilepsy NaviFUS System - Drug Resistant Epilepsy, Epilepsy | Phase 1 / Phase 2 | Recruiting | NaviFUS Corporation | 8 | 2024-09-13 | 2026-09-15 |
| An Open Label, Balanced, Randomized, 3×3 Latin Square Design Comparing of Brivaracetam Sustained-release Tablets and Brivaracetam Tablets in the Oral Comparative Pharmacokinetic(PK) Study in Chinese Healthy Adult Subjects Under Fasting Conditions. Brivaracetam tablets (50mg/ tablet, BRIVIACT®, UCB), Brivaracetam sustained-release tablets 100mg, Brivaracetam sustained-release tablets 50mg - Partial Seizure | Phase 1 | Unknown | Overseas Pharmaceuticals, Ltd. | 12 | 2022-09-13 | 2023-02-01 |
| Study of Midazolam in Healthy Adults Midazolam, Seizalam - Status Epilepticus | Phase 1 | Completed | Rafa Laboratories | 40 | 2021-06-09 | 2022-03-17 |
| Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects With Partial-Onset Seizures Xcopri - Partial Epilepsy | Phase 1 | Completed | SK Life Science, Inc. | 26 | 2021-05-27 | 2026-03-31 |
| Effect of Perampanel on Peritumoral Hyperexcitability in HGG Perampanel, Standard of Care - Glioma, Malignant, Surgery | Phase 1 / Phase 2 | Completed | Dana-Farber Cancer Institute | 12 | 2020-11-05 | 2024-08-05 |
| Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S QBS10072S - Astrocytoma, Brain Cancer | Phase 1 | Completed | Quadriga Biosciences, Inc. | 15 | 2020-07-20 | 2023-01-18 |
| Pilot Trial to Evaluate The Effect of Oral Methylprednisolone on Seizure Frequency in Children With Epilepsy methylprednisolone sodium succinate, Placebo - Intractable Epilepsy, Convulsive Seizures | Phase 1 / Phase 2 | Unknown | Louisiana State University Health Sciences Center in New Orleans | 10 | 2020-02-03 | 2020-02-07 |
| BIS-001-ER for the Treatment of Adult Focal Impaired Awareness Seizures BIS-001ER - Focal Impaired Awareness Seizures | Phase 1 / Phase 2 | Active not recruiting | Supernus Pharmaceuticals, Inc. | 16 | 2018-04-10 | 2022-08-30 |
| Repeat-Dose Pharmacokinetics Study of NRL-1 in Epilepsy Subjects NRL-1 - Acute Repetitive Seizures | Phase 1 | Completed | Neurelis, Inc. | 57 | 2016-06-30 | 2021-10-05 |
| Levetiracetam Treatment of Neonatal Seizures Oral levetiracetam, Intravenous phenobarbital - Neonatal Seizures | Phase 1 / Phase 2 | Terminated | Children's Hospital of Fudan University | 60 | 2015-09-01 | 2023-12-29 |
| Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders Cannabidiol Oral Solution - Seizures | Phase 1 / Phase 2 | Completed | INSYS Therapeutics Inc | 61 | 2015-04-13 | 2017-06-23 |
Showing 20 of 46. Sign in to see all of them.
Epilepsy (17) · Drug Resistant Epilepsy (5) · Status Epilepticus (3) · Bipolar Disorder (2) · Acidosis, Lactic (1) · Anorexia (1) · Anxiety Disorders (1) · Astrocytoma (1) · Brain Injuries (1) · Brain Neoplasms (1) · Breast Neoplasms (1) · Central Nervous System Diseases (1) · Cerebral Palsy (1) · Cholangiocarcinoma (1)
Nervous System Diseases (46) · Neurologic Manifestations (46) · Pathological Conditions, Signs and Symptoms (46) · Signs and Symptoms (46) · Brain Diseases (24) · Central Nervous System Diseases (23) · Cardiovascular Diseases (4) · Cerebrovascular Disorders (3) · Epilepsy (3) · Mental Disorders (3) · Vascular Diseases (3) · Acid-Base Imbalance (2) · Acidosis (2) · Bipolar and Related Disorders (2)
Levetiracetam (6) · Cannabidiol (4) · Midazolam (2) · Oxcarbazepine (2) · Phenobarbital (2) · Tablets (2) · Topiramate (2) · Bumetanide (1) · Cenobamate (1) · Circulatory Arrest, Deep Hypothermia Induced (1) · Dexmedetomidine (1) · Diet, Ketogenic (1) · Gadolinium (1) · Health Services Needs and Demand (1) · Lamotrigine (1)
Richard H. Haas (2) · Roxane Laboratories (2) · Sandoz (2) · Supernus Pharmaceuticals, Inc. (2) · University of Alabama at Birmingham (2) · Avata Biosciences Holdings Ltd (1) · Children's Hospital Medical Center, Cincinnati (1) · Children's Hospital of Fudan University (1) · Dana-Farber Cancer Institute (1) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (1) · George Washington University (1) · GlaxoSmithKline (1) · Heather Olson (1) · INSYS Therapeutics Inc (1) · Jazz Pharmaceuticals (1)
United States (30) · Australia (4) · China (2) · Brazil (1) · Hungary (1) · Malawi (1) · Singapore (1) · South Korea (1) · Taiwan (1)
Cynthia Zamora, MD (2) · Alana M Flexman, MD (1) · Anne Chiaramello, Ph.D. (1) · Azmi Nasser, PhD (1) · Colin VanOrman, MD (1) · Debra Regier, M.D., Ph.D. (1) · Eric H Kossoff, MD (1) · Francis Filloux, MD (1) · Gaetano Morelli, M.D. (1) · Gretchen L Birbeck, M.D. (1) · Henk de Wilde (1) · Imran Quraishi, MD, PhD (1) · James Chamberlain, MD (1) · Janet Soul, MD,CM (1)
PMID 29063814, PMID 31048098, PMID 18778916, PMID 21673279, PMID 22495532, PMID 22633629, PMID 23642342, PMID 26187603, PMID 28500900, PMID 29933272, PMID 30289769, PMID 31049885, PMID 31672143, PMID 34119901, PMID 38902005, PMID 39499201
P50CA165962 (1), R01NS066929 (1), R01NS074409 (1), UH3TR003897 (1)